|
Randomized Trial of Aspirin and Cataracts in U.S. Physicians Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Randomized Trial of Aspirin and Cataracts in U.S. Physicians conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Randomized Trial of Aspirin and Cataracts in U.S. Physicians Clinical research trials and Randomized Trial of Aspirin and Cataracts in U.S. Physicians healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Randomized Trial of Aspirin and Cataracts in U.S. Physicians. Randomized Trial of Aspirin and Cataracts in U.S. Physicians Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Randomized Trial of Aspirin and Cataracts in U.S. Physicians clinical trial. Test subjects typically receive the most effective healthcare possible for their Randomized Trial of Aspirin and Cataracts in U.S. Physicians condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Randomized Trial of Aspirin and Cataracts in U.S. Physicians  Randomized Trial of Aspirin and Cataracts in U.S. Physicians
Randomized Trial of Aspirin and Cataracts in U.S. Physicians
For Condition: Cataract
Status: Completed
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery.
Details: Cataract is one of the most common causes of impaired vision as well as the third leading cause of blindness in the United States. Cataract surgery is one of the safest and most successful of all operations. The National Eye Institute has estimated that if the progression of cataract could be slowed enough to delay the need for surgery by even 10 years, the current annual number could be reduced by 45 percent. Little is known about the relative importance of various potential risk factors in the development of cataract. Most current information on risk factors has come from anecdotal reports or from relatively small case-control studies. One major project, the Framingham Eye Study, has identified several factors that were significantly associated with subsequent cataract formation, including diabetes and dietary factors. Diabetes has long been thought to increase the risk of developing cataract. Recently, aspirin has been proposed as a drug that can prevent cataract formation or slow its progression. Aspirin may affect tryptophan levels in patients with cataract, or it may inhibit aldose reductase, an enzyme associated with the development of diabetic cataract. Thus, data from this study sought to determine whether one 325-mg aspirin tablet, taken on alternate days, protects against cataract formation. The data also sought to reveal other additional cataract risk factors that emerge after simultaneous controlling for other variables. The other primary objective of this trial was to assess the antioxidant effects of beta-carotene (50 mg on alternate days) on cataract development. In addition, factors that have been suggested to be cataractogenic were assessed in prospective cohort studies. These factors included age, blood pressure, blood cholesterol, height, diabetes, medication use, cigarette smoking, and history of previous eye trauma or surgery. In addition, the possible associations between history of vitamin E and selenium intake and cataract were explored. This trial was part of the Physicians Health Study, an ongoing, randomized, placebo-controlled clinical trial of aspirin in the prevention of cardiovascular mortality and of beta-carotene in the prevention of cancer. Following randomization, each of the 22,071 physicians enrolled was assigned to one of four groups to take either aspirin or its placebo and beta-carotene or its placebo. Follow-up questionnaires were sent 6 and 12 months after randomization and every 12 months thereafter. The randomized aspirin component of the trial was terminated early (January 1988), after an average followup of approximately 5 years, because of a statistically extreme 44 percent reduced risk of a first myocardial infarction in the aspirin group. Since this study is conducted by mail among physicians nationwide, examinations cannot be performed on all patients to determine when they have reached an end point. Reported diagnoses of cataract are confirmed by medical record review. The primary analysis will be of incidence of cataract in the aspirin and placebo groups. In addition, the Cox proportional hazards model will be used to determine whether there is a difference in time to cataract diagnosis between the two groups. It has been postulated that the potent antioxidant properties of beta-carotene might make it effective in preventing cataract development. The investigators will thus determine whether there is a difference in the numbers of cataracts between the beta-carotene/placebo groups and the aspirin/placebo groups.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Placebo Control
Minimum Age/Maximum Age: 40 Years/84 Years
Genders: Male
Protocol Entry Criteria: The study population consisted of 22,071 male U.S. physicians, aged 40 to 84 years in 1982, with no history of myocardial infarction, cancer, kidney disease, renal disease, or any other contraindication to the use of aspirin or beta-carotene, including regular use of corticosteroids.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: NEI-59;
Study Start Date: April 1982
Record last reviewed: September 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000157
Other Cataract Studies:
1. Age-Related Macular Degeneration and Cataract
2. Randomized Trial of Aspirin and Cataracts in U.S. Physicians
3. Clinical and Genetic Studies of Families with Congenital or Hereditary Cataracts
4. Test of QLS Device to Detect Early Cataracts
5. Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts
Related Studies:
Other Cataract Clinical Trials
Other Clinical Trials
Other Clinical Trials
Randomized Trial of Aspirin and Cataracts in U.S. Physicians
|
|
|
|
|
|
|
|
